GenoSpace Completes Financing with Thomson Reuters

genospace-logoGenoSpace, a Cambridge, MA-based precision medicine software company that has developed a comprehensive suite of tools to enable the broad use of genomic data in research and clinical care, completed a financing deal with Thomson Reuters.

The amount of the transaction, which marks the first investment in the precision medicine informatics market by Thomson Reuters, was not disclosed.

The company intends to use the funds to accelerate expansion of its customer base in research, clinical development, laboratory medicine and clinical care.

Led by John Quackenbush, CEO, GenoSpace provides a unified software platform that addresses the data access, analysis, interpretation and reporting needs of a diverse group of users including research scientists, pathologists, oncologists, clinical trial specialists, medical directors and patients.



Join the discussion